Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications. It also provides IHEEZO, a chloroprocaine hydrochloride ophthalmic gel; ophthalmic solutions, including IOPIDINE, VEVYE, and ZERVIATE, as well as BYQLOVI; MAXITROL eye drops; ILEVRO and NEVANAC, a non-steroidal and anti-inflammatory eye drop for pain and inflammation associated with cataract surgery; BYOOVIZ, a LUCENTIS biosimilar indicated for the treatment of patients with Neovascular (Wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), and myopic choroidal neovascularization (mCNV); VIGAMOX, a fluoroquinolone antibiotic eye drop for the treatment of bacterial conjunctivitis; OPUVIZ, an EYLEA biosimilar indicated for the treatment of patients with Wet AMD, macular edema following RVO, diabetic macular edema (DME), and diabetic retinopathy (DR); MAXIDEX and FLAREX, a steroid eye drop for steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe and the eye; TRIESENCE, a steroid injection for the treatment of ophthalmic diseases and for visualization during vitrectomy; and NATACYN, a sterile, antifungal drug for the treatment of fungal blepharitis, conjunctivitis, and keratitis. In addition, it offers TOBRADEX ST, a tobramycin and dexamethasone ophthalmic suspension; VERKAZIA cyclosporine ophthalmic emulsion; NEVANAC, a non-steroidal, anti-inflammatory eye drop; and FRESHKOTE preservative free (PF) is a lubricant eye drop. The company was formerly known as Harrow Health, Inc. and changed its name to Harrow, Inc. in September 2023. Harrow, Inc. was founded in 1998 and is headquartered in Nashville, Tennessee.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 5 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $272M | $42M | $-5M | $43M | -9.8% | 36.4% | -70.6% |
| 2024 | $200M | $20M | $-17M | $-61M | -25.1% | 53.3% | -28.4% |
| 2023 | $130M | $10M | $-24M | $-149M | -34.5% | 47.0% | 73.3% |
| 2022 | $89M | $-3M | $-14M | $-6M | -51.0% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 272.30 |
| Operating Revenue | 271.91 |
| Cost Of Revenue | 67.93 |
| Gross Profit | 204.37 |
| Operating Expense | 173.85 |
| Research And Development | 20.94 |
| Selling General And Administration | 152.91 |
| Total Expenses | 241.79 |
| Operating Income | 30.52 |
| Total Operating Income As Reported | 30.52 |
| EBITDA | 42.49 |
| Normalized EBITDA | 50.24 |
| EBIT | 22.81 |
| Interest Expense | 24.18 |
| Net Interest Income | -24.18 |
| Other Non Operating Income Expenses | 0.05 |
| Other Income Expense | -7.70 |
| Interest Expense Non Operating | 24.18 |
| Net Non Operating Interest Income Expense | -24.18 |
| Pretax Income | -1.37 |
| Tax Provision | 3.77 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -1.63 |
| Net Income Continuous Operations | -5.14 |
| Net Income From Continuing And Discontinued Operation | -5.14 |
| Net Income From Continuing Operation Net Minority Interest | -5.14 |
| Net Income | -5.14 |
| Net Income Common Stockholders | -5.14 |
| Net Income Including Noncontrolling Interests | -5.14 |
| Normalized Income | 0.98 |
| Diluted NI Availto Com Stockholders | -5.14 |
| Basic Average Shares | 36.71 |
| Diluted Average Shares | 36.71 |
| Reconciled Depreciation | 19.68 |
| Reconciled Cost Of Revenue | 67.93 |
| Total Unusual Items | -7.75 |
| Total Unusual Items Excluding Goodwill | -7.75 |
| Preferred Stock Dividends | - |
| Minority Interests | - |
| Special Income Charges | -7.75 |
| Other Special Charges | 7.75 |
| Impairment Of Capital Assets | 0 |
| Gain On Sale Of Security | - |
| Gain On Sale Of Ppe | - |
| Total Other Finance Cost | - |
| Earnings From Equity Interest | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Harrow, Inc.this co. | HROW | $1.3B | -251.62 | 24.66 | -9.8% | 34.65 |
| Inhibrx Biosciences, Inc. | INBX | $1.3B | -9.56 | 167.49 | -1752.2% | -10.54 |
| Ardelyx, Inc. | ARDX | $1.3B | -21.66 | 7.99 | -36.9% | -50.52 |
| Tandem Diabetes Care, Inc. | TNDM | $1.3B | -6.51 | 8.59 | -131.9% | -9.55 |
| AdaptHealth Corp. | AHCO | $1.3B | -18.70 |
| - |
| - |
| - |
| - |
| 0.87 |
| -4.7% |
| 6.60 |
| BioLife Solutions, Inc. | BLFS | $1.3B | -288.04 | 3.56 | -1.2% | -109.81 |
| Teladoc Health, Inc. | TDOC | $1.3B | -6.59 | 0.95 | -14.5% | 9.83 |
| Enovis Corporation | ENOV | $1.3B | -1.11 | 0.88 | -79.5% | -3.20 |
| Personalis, Inc. | PSNL | $1.3B | -15.59 | 4.85 | -31.1% | -16.66 |
| Peer Median | - | -12.58 | 4.21 | -34.0% | -10.05 | |